SLC5A2 and type 2 diabetes mellitus: As a result, ESC guidelines for the treatment of HF, released in mid-2021, recommend all SGLT2 inhibitor class (empagliflozin, dapagliflozin, canagliflozin, ertugliflozin, and sotagliflozin) to reduce hospitalizations for HF, major CV events, and death in patients with T2DM who are at the risk of CV events (15).